{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:58:16Z","timestamp":1783576696174,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-004"],"award-info":[{"award-number":["2022-PUMCH-C-004"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["3332022110"],"award-info":[{"award-number":["3332022110"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2021-I2M-1-016"],"award-info":[{"award-number":["2021-I2M-1-016"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}]},{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-A-008"],"award-info":[{"award-number":["2022-I2M-C&T-A-008"]}]},{"name":"Beijing Natural Science Foundation","award":["M22035"],"award-info":[{"award-number":["M22035"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272046"],"award-info":[{"award-number":["82272046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00259-023-06283-4","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:02:11Z","timestamp":1685080931000},"page":"3126-3136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET\/CT in patients with primary prostate cancer"],"prefix":"10.1007","volume":"50","author":[{"given":"Guochang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"6283_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339. https:\/\/doi.org\/10.1002\/jcb.10661.","journal-title":"J Cell Biochem"},{"key":"6283_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2021.03.055","volume":"111","author":"SC Masters","year":"2021","unstructured":"Masters SC, Hofling AA, Gorovets A, Marzella L. FDA approves Ga 68 PSMA-11 for prostate cancer imaging. Int J Radiat Oncol Biol Phys. 2021;111:27\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.055.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6283_CR3","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.2967\/jnumed.122.264299","volume":"63","author":"AA Hofling","year":"2022","unstructured":"Hofling AA, Fotenos AF, Niu G, Fallah J, Agrawal S, Wang SJ, et al. Prostate cancer theranostics: concurrent approvals by the Food and Drug Administration of the first diagnostic imaging drug indicated to select patients for a paired radioligand therapeutic drug. J Nucl Med. 2022;63:1642\u20133. https:\/\/doi.org\/10.2967\/jnumed.122.264299.","journal-title":"J Nucl Med"},{"key":"6283_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"6283_CR5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.021.","journal-title":"Eur Urol"},{"key":"6283_CR6","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58:1962\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"key":"6283_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","volume":"49","author":"DA Pattison","year":"2022","unstructured":"Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL, et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:763\u201376. https:\/\/doi.org\/10.1007\/s00259-021-05520-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776\u201387. https:\/\/doi.org\/10.1007\/s00259-016-3594-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR9","doi-asserted-by":"publisher","unstructured":"Noto B, Buther F, Auf der Springe K, Avramovic N, Heindel W, Schafers M, et al. Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI. EJNMMI Res. 2017;7:12. https:\/\/doi.org\/10.1186\/s13550-017-0261-8.","DOI":"10.1186\/s13550-017-0261-8"},{"key":"6283_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","volume":"24","author":"H Lee","year":"2022","unstructured":"Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, et al. Preliminary evaluation of 68Ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate cancer. Mol Imaging Biol. 2022;24:710\u201320. https:\/\/doi.org\/10.1007\/s11307-022-01720-6.","journal-title":"Mol Imaging Biol"},{"key":"6283_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","volume":"59","author":"Z Zha","year":"2018","unstructured":"Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF. Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor. Nucl Med Biol. 2018;59:36\u201347. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.007.","journal-title":"Nucl Med Biol"},{"key":"6283_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11307-019-01421-7","volume":"22","author":"MA Green","year":"2020","unstructured":"Green MA, Hutchins GD, Bahler CD, Tann M, Mathias CJ, Territo W, et al. [68Ga]Ga-P16-093 as a PSMA-targeted PET radiopharmaceutical for detection of cancer: initial evaluation and comparison with [68Ga]Ga-PSMA-11 in prostate cancer patients presenting with biochemical recurrence. Mol Imaging Biol. 2020;22:752\u201363. https:\/\/doi.org\/10.1007\/s11307-019-01421-7.","journal-title":"Mol Imaging Biol"},{"issue":"48","key":"6283_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2022.10.003","volume":"41","author":"CD Bahler","year":"2023","unstructured":"Bahler CD, Green MA, Tann MA, Swensson JK, Collins K, Alexoff D, et al. Assessing extra-prostatic extension for surgical guidance in prostate cancer: comparing two PSMA-PET tracers with the standard-of-care. Urol Oncol. 2023;41(48):e1\u20139. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.003.","journal-title":"Urol Oncol"},{"key":"6283_CR14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","volume":"49","author":"G Wang","year":"2022","unstructured":"Wang G, Hong H, Zang J, Liu Q, Jiang Y, Fan X, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2022;49:1052\u201362. https:\/\/doi.org\/10.1007\/s00259-021-05539-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/RLU.0000000000004566","volume":"48","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Zang J, Hong H, Zhu L, Kung HF, et al. Head-to-head comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET\/CT in patients with primary prostate cancer\u202f: a pilot study. Clin Nucl Med. 2023;48:289\u201395. https:\/\/doi.org\/10.1097\/RLU.0000000000004566.","journal-title":"Clin Nucl Med"},{"key":"6283_CR16","doi-asserted-by":"publisher","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479\u2013505. https:\/\/doi.org\/10.6004\/jnccn.2019.0023.","DOI":"10.6004\/jnccn.2019.0023"},{"key":"6283_CR17","doi-asserted-by":"publisher","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","DOI":"10.1007\/s00259-017-3670-z"},{"key":"6283_CR18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2967\/jnumed.120.258434","volume":"62","author":"M Suh","year":"2021","unstructured":"Suh M, Im HJ, Ryoo HG, Kang KW, Jeong JM, Prakash S, et al. Head-to-head comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study. J Nucl Med. 2021;62:1457\u201360. https:\/\/doi.org\/10.2967\/jnumed.120.258434.","journal-title":"J Nucl Med"},{"key":"6283_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","volume":"61","author":"I Sonni","year":"2020","unstructured":"Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of 68Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153\u201360. https:\/\/doi.org\/10.2967\/jnumed.119.237602.","journal-title":"J Nucl Med"},{"key":"6283_CR20","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3631-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018;59:238\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.195172.","journal-title":"J Nucl Med"},{"key":"6283_CR22","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","volume":"38","author":"D Kaemmerer","year":"2011","unstructured":"Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET\/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:1659\u201368. https:\/\/doi.org\/10.1007\/s00259-011-1846-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"6283_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiol.2018172232","volume":"288","author":"SY Park","year":"2018","unstructured":"Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, et al. Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018;288:495\u2013505. https:\/\/doi.org\/10.1148\/radiol.2018172232.","journal-title":"Radiology"},{"key":"6283_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13550-022-00881-3","volume":"12","author":"C Zhou","year":"2022","unstructured":"Zhou C, Tang Y, Deng Z, Yang J, Zhou M, Wang L, et al. Comparison of 68Ga-PSMA PET\/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Res. 2022;12:10. https:\/\/doi.org\/10.1186\/s13550-022-00881-3.","journal-title":"EJNMMI Res"},{"key":"6283_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-019-04524-z","volume":"47","author":"W Cytawa","year":"2020","unstructured":"Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, et al. 68Ga-PSMA I&T PET\/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:168\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04524-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2967\/jnumed.120.245605","volume":"62","author":"S Klingenberg","year":"2021","unstructured":"Klingenberg S, Jochumsen MR, Ulhoi BP, Fredsoe J, Sorensen KD, Borre M, et al. 68Ga-PSMA PET\/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer. J Nucl Med. 2021;62:214\u201320. https:\/\/doi.org\/10.2967\/jnumed.120.245605.","journal-title":"J Nucl Med"},{"key":"6283_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/jnumed.119.234187.","journal-title":"J Nucl Med"},{"key":"6283_CR29","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192\u20138.","journal-title":"Cancer Res"},{"key":"6283_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00259-022-06101-3","volume":"50","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Wang J, Zang J, Chen J, Xiao Y, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET\/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499\u2013509. https:\/\/doi.org\/10.1007\/s00259-022-06101-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6283_CR31","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","volume":"45","author":"P Caroli","year":"2018","unstructured":"Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, et al. 68Ga-PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. 2018;45:2035\u201344. https:\/\/doi.org\/10.1007\/s00259-018-4067-3.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06283-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06283-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:57:50Z","timestamp":1744214270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06283-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6283"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06283-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. ZS-2461), and this study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Hank F. Kung is the founder of Five Eleven Pharma, which holds the patent rights for [68Ga]Ga-P16-093 and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}